From MarketBeat:

Oppenheimer & Co. Inc. increased its position in shares of Abbott Laboratories by 7.0% during the third quarter, according to the company’s most recent Form 13F filing with the SEC. Other institutional investors including Halpern Financial Inc. and Altshuler Shaham Ltd also recently bought shares. Abbott Laboratories stock is down 1.5%. NYSE:ABT traded down $1.72 during mid-day trading on Friday, reaching $112.77. The stock had a trading volume of 1,709,729 shares, compared to its average volume of 5,174,077. Abbott Laboratories Increases Dividend – Abbott Laboratories has declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a $0.55 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.51. Analyst Upgrades and Downgrades – Several brokerages have commented on ABT, and the stock currently has an average rating of “Moderate Buy” and an average price target of $120.00. Insider Activity at Abbott Laboratories – EVP Andrea F. Wainer sold a significant amount of shares, as reported in a transaction. Abbott Laboratories operates in four segments and provides a variety of healthcare products worldwide. The company had revenue of $10.24 billion during the quarter. 73.70% of the stock is currently owned by institutional investors and hedge funds. Abbott Laboratories shares are currently rated as a “Moderate Buy.”



Read more: Oppenheimer & Co. Inc. Raises Stake in Abbott Laboratories (NYSE:ABT)